Market Overview

Jazz Pharma Begins Trial of IV Administered Erwinaze

Related JAZZ
12 Biggest Mid-Day Gainers For Thursday
UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma
The Vetr community has downgraded $JAZZ to 3-Stars (Vetr)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze^® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

Posted-In: News FDA


Related Articles (JAZZ)

View Comments and Join the Discussion!